Review
Gynaecological malignancies and sentinel lymph node mapping: an update
Elizabeth D Euscher,
Anais Malpica,
Elizabeth D Euscher
Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Search for more papers by this authorCorresponding Author
Anais Malpica
Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Address for correspondence: A Malpica, Department of Pathology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 085, Houston, TX 77030, USA. e-mail: [email protected]
Search for more papers by this authorElizabeth D Euscher,
Anais Malpica,
Elizabeth D Euscher
Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Search for more papers by this authorCorresponding Author
Anais Malpica
Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Address for correspondence: A Malpica, Department of Pathology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 085, Houston, TX 77030, USA. e-mail: [email protected]
Search for more papers by this authorAbstract
Assessment of pelvic, para-aortic or inguinal lymph nodes (LNs) provides not only important prognostic information, but also determines the need for adjuvant treatment. Sentinel lymph node (SLN) biopsy has the potential to provide this prognostic information, while reducing morbidity compared with extended LN dissection. This review discusses the clinical and pathological aspects of SLN biopsy in gynaecological cancer.
References
- 1Slomovitz BM, Coleman RL, Oonk MH et al. Update on sentinel lymph node biopsy for early-stage vulvar cancer. Gynecol. Oncol. 2015; 138; 472–477.
- 2Roy M, Bouchard-Fortier G, Popa I et al. Value of sentinel node mapping in cancer of the cervix. Gynecol. Oncol. 2011; 122; 269–274.
- 3Euscher E, Sui DW, Soliman P et al. Ultrastaging of sentinel lymph nodes in endometrial carcinoma according to use of 2 different methods. Int. J. Gynecol. Pathol. 2018; 37; 242–251.
- 4Abu-Rustum NR, Yashar CM, Bean S et al. NCCN guidelines, version 4.2019. Uterine neoplasms/endometrial carcinoma. Plymouth Meeting, PA: National Comprehensive Cancer Network (NCCN), 2019.
- 5Kim CH, Soslow RA, Park KJ et al. Pathologic ultrastaging improves micrometastasis detection in sentinel lymph nodes during endometrial cancer staging. Int. J. Gynecol. Cancer 2013; 23; 964–970.
- 6Euscher ED, Malpica A, Atkinson EN et al. Ultrastaging improves detection of metastases in sentinel lymph nodes of uterine cervix squamous cell carcinoma. Am. J. Surg. Pathol. 2008; 32; 1336–1343.
- 7Oonk MH, van Hemel BM, Hollema H et al. Size of sentinel-node metastasis and chances of non-sentinel-node involvement and survival in early stage vulvar cancer: results from GROINSS-V, a multicentre observational study. Lancet Oncol. 2010; 11; 646–652.
- 8Levenback CF, Ali S, Coleman RL et al. Lymphatic mapping and sentinel lymph node biopsy in women with squamous cell carcinoma of the vulva: a Gynecologic Oncology Group study. J. Clin. Oncol. 2012; 30; 3786–3791.
- 9Salvo G, Ramirez PT, Levenback CF et al. Sensitivity and negative predictive value for sentinel lymph node biopsy in women with early-stage cervical cancer. Gynecol. Oncol. 2017; 145; 96–101.
- 10Hassanzadeh M, Farahabadi EH, Yousefi Z et al. Lymphatic mapping and sentinel node biopsy in ovarian tumors: a study using intra-operative Tc-99m-Phytate and lymphoscintigraphy imaging. J. Ovarian Res. 2016; 9; 55.
- 11Levenback C, Burke TW, Gershenson DM et al. Intraoperative lymphatic mapping for vulvar cancer. Obstet. Gynecol. 1994; 84; 163–167.
- 12Vidal-Sicart S, Puig-Tintore LM, Lejarcegui JA et al. Validation and application of the sentinel lymph node concept in malignant vulvar tumours. Eur. J. Nucl. Med. Mol. Imaging 2007; 34; 384–391.
- 13Hampl M, Hantschmann P, Michels W et al. Validation of the accuracy of the sentinel lymph node procedure in patients with vulvar cancer: results of a multicenter study in Germany. Gynecol. Oncol. 2008; 111; 282–288.
- 14Van der Zee AG, Oonk MH, De Hullu JA et al. Sentinel node dissection is safe in the treatment of early-stage vulvar cancer. J. Clin. Oncol. 2008; 26; 884–889.
- 15Achimas-Cadariu P, Harter P, Fisseler-Eckhoff A et al. Assessment of the sentinel lymph node in patients with invasive squamous carcinoma of the vulva. Acta Obstet. Gynecol. Scand. 2009; 88; 1209–1214.
- 16Devaja O, Mehra G, Coutts M et al. A prospective study of sentinel lymph node detection in vulval carcinoma: is it time for a change in clinical practice? Int. J. Gynecol. Cancer 2011; 21; 559–564.
- 17Euscher E, Malpica A. Is there a role for exhaustive ultrastaging of sentinel lymph nodes in vulvar cancer? Mod. Pathol. 2018; 31; 419.
- 18Koh WJ, Abu-Rustum NR, Bean S et al. NCCN guidelines. Version 2.2019 in Vulvar carcinoma (squamous cell carcinoma). Plymouth Meeting, PA: National Comprehensive Cancer Network (NCCN), 2019.
- 19Euscher E, Malpica A. Is there a role for exhaustive ultrastaging of sentinel lymph nodes in vulvar cancer? Lab. Invest. 2018; 98; 419.
- 20Nica A, Covens A, Vicus D et al. Sentinel lymph nodes in vulvar cancer: management dilemmas in patients with positive nodes and larger tumors. Gynecol. Oncol. 2019; 152; 94–100.
- 21Swetter SM, Tsao H, Bichakjian CK et al. Guidelines of care for the management of primary cutaneous melanoma. J. Am. Acad. Dermatol. 2019; 80; 208–250.
- 22Frumovitz M, Gayed IW, Jhingran A et al. Lymphatic mapping and sentinel lymph node detection in women with vaginal cancer. Gynecol. Oncol. 2008; 108; 478–481.
- 23Ishida H, Nagai T, Sato S et al. Concomitant sentinel lymph node biopsy leading to abbreviated systematic lymphadenectomy in a patient with primary malignant melanoma of the vagina. Springerplus 2015; 4; 102.
- 24Lee IO, Lee JY, Kim S et al. Sentinel lymph node mapping with indocyanine green in vaginal cancer. J. Gynecol. Oncol. 2017; 28; e29.
- 25Nakagawa S, Koga K, Kugu K et al. The evaluation of the sentinel node successfully conducted in a case of malignant melanoma of the vagina. Gynecol. Oncol. 2002; 86; 387–389.
- 26van Dam P, Sonnemans H, van Dam PJet al. Sentinel node detection in patients with vaginal carcinoma. Gynecol. Oncol. 2004; 92; 89–92.
- 27Cibula D, Abu-Rustum NR, Dusek L et al. Prognostic significance of low volume sentinel lymph node disease in early-stage cervical cancer. Gynecol. Oncol. 2012; 124; 496–501.
- 28Lecuru F, Mathevet P, Querleu D et al. Bilateral negative sentinel nodes accurately predict absence of lymph node metastasis in early cervical cancer: results of the SENTICOL study. J. Clin. Oncol. 2011; 29; 1686–1691.
- 29Lecuru FR, McCormack M, Hillemanns P et al. SENTICOL III: an international validation study of sentinel node biopsy in early cervical cancer. A GINECO, ENGOT, GCIG and multicenter study. Int. J. Gynecol. Cancer 2019; 29; 829–834.
- 30Koh WJ, Abu-Rustum NR, Bean S et al. NCCN guidelines, version 5.2019 in cervical cancer. Plymouth Meeting, PA: National Comprehensive Cancer Network (NCCN), 2019; 17; 64–84.
- 31 National Comprehensive Cancer Network (NCCN). NCCN publishes new clinical practice guidelines for vulvar cancer. J. Natl Compr. Cancer Netw. 2016; 14; xxxv–xl.
- 32Cibula D, Abu-Rustum NR, Dusek L et al. Bilateral ultrastaging of sentinel lymph node in cervical cancer: lowering the false-negative rate and improving the detection of micrometastasis. Gynecol. Oncol. 2012; 127; 462–466.
- 33Creasman WT, Morrow CP, Bundy BN et al. Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group study. Cancer 1987; 60; 2035–2041.
10.1002/1097-0142(19901015)60:8+<2035::AID-CNCR2820601515>3.0.CO;2-8 CAS PubMed Web of Science® Google Scholar
- 34Morrow CP, Bundy BN, Kurman RJ et al. Relationship between surgical pathological risk-factors and outcome in clinical stage-I and stage-II carcinoma of the endometrium – a Gynecologic Oncology Group study. Gynecol. Oncol. 1991; 40; 55–65.
- 35Mariani A, Dowdy SC, Cliby WA et al. Prospective assessment of lymphatic dissemination in endometrial cancer: a paradigm shift in surgical staging. Gynecol. Oncol. 2008; 109; 11–18.
- 36Nofech-Mozes S, Ghorab Z, Ismiil N et al. Endometrial endometrioid adenocarcinoma: a pathologic analysis of 827 consecutive cases. Am. J. Clin. Pathol. 2008; 129; 110–114.
- 37Benedetti Panici P, Basile S, Maneschi F et al. Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J. Natl Cancer Inst. 2008; 100; 1707–1716.
- 38Holloway RW, Abu-Rustum NR, Backes FJ et al. Sentinel lymph node mapping and staging in endometrial cancer: a Society of Gynecologic Oncology literature review with consensus recommendations. Gynecol. Oncol. 2017; 146; 405–415.
- 39Abu-Rustum NR, Khoury-Collado F, Pandit-Taskar N et al. Sentinel lymph node mapping for grade 1 endometrial cancer: is it the answer to the surgical staging dilemma? Gynecol. Oncol. 2009; 113; 163–169.
- 40Ballester M, Dubernard G, Lecuru F et al. Detection rate and diagnostic accuracy of sentinel-node biopsy in early stage endometrial cancer: a prospective multicentre study (SENTI-ENDO). Lancet Oncol. 2011; 12; 469–476.
- 41Holloway RW, Bravo RA, Rakowski JA et al. Detection of sentinel lymph nodes in patients with endometrial cancer undergoing robotic-assisted staging: a comparison of colorimetric and fluorescence imaging. Gynecol. Oncol. 2012; 126; 25–29.
- 42Holloway RW, Gupta S, Stavitzski NM et al. Sentinel lymph node mapping with staging lymphadenectomy for patients with endometrial cancer increases the detection of metastasis. Gynecol. Oncol. 2016; 141; 206–210.
- 43Koskas M, Chereau E, Ballester M et al. Accuracy of a nomogram for prediction of lymph-node metastasis detected with conventional histopathology and ultrastaging in endometrial cancer. Br. J. Cancer 2013; 108; 1267–1272.
- 44Naoura I, Canlorbe G, Bendifallah S et al. Relevance of sentinel lymph node procedure for patients with high-risk endometrial cancer. Gynecol. Oncol. 2015; 136; 60–64.
- 45Touhami O, Trinh XB, Gregoire J et al. Predictors of non-sentinel lymph node (non-SLN) metastasis in patients with sentinel lymph node (SLN) metastasis in endometrial cancer. Gynecol. Oncol. 2015; 138; 41–45.
- 46Frimer M, Khoury-Collado F, Murray MP et al. Micrometastasis of endometrial cancer to sentinel lymph nodes: is it an artifact of uterine manipulation? Gynecol. Oncol. 2010; 119; 496–499.
- 47Plante M, Stanleigh J, Renaud MCet al. Isolated tumor cells identified by sentinel lymph node mapping in endometrial cancer: does adjuvant treatment matter? Gynecol. Oncol. 2017; 146; 240–246.
- 48Espinosa I, Serrat N, Zannoni GFet al. Endometrioid endometrial carcinomas with microcystic, elongated, and fragmented (MELF) type of myoinvasion: role of immunohistochemistry in the detection of occult lymph node metastases and their clinical significance. Hum. Pathol. 2017; 70; 6–13.
- 49Kennard JA, Stephens AJ, Ahmad S et al. Sentinel lymph nodes (SLN) in endometrial cancer: The relationship between primary tumor histology, SLN metastasis size, and non-sentinel node metastasis. Gynecol. Oncol. 2019; 154; 53–59.
- 50Dell'Orto F, Laven P, Delle Marchette M et al. Feasibility of sentinel lymph node mapping of the ovary: a systematic review. Int. J. Gynecol. Cancer 2019; 29; 1209–1215.
- 51Uccella S, Nero C, Vizza E et al. Sentinel-node biopsy in early-stage ovarian cancer: preliminary results of a prospective multicentre study (SELLY). Am. J. Obstet. Gynecol. 2019; 221; 324.e1–324.10.
- 52Kleppe M, Wang T, Van Gorp T et al. Lymph node metastasis in stages I and II ovarian cancer: a review. Gynecol. Oncol. 2011; 123; 610–614.
- 53Schmeler KM, Tao X, Frumovitz M et al. Prevalence of lymph node metastasis in primary mucinous carcinoma of the ovary. Obstet. Gynecol. 2010; 116; 269–273.
- 54Uccella S, Fagotti A, Zannoni GF et al. Presumed early ovarian cancer with isolated tumor cells in para-aortic sentinel nodes. Int. J. Gynecol. Cancer 2019; 2; 216–220.
